Medical Doctor Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

James McMurtrie

Sports Medicine Huntsville, AL Medical Doctor

NPI 1972967578 CMS profile 10112114

927 Franklin St Se, Huntsville, AL 35801

Open in the dashboard

General payments

$53,619

72 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, James McMurtrie of Huntsville, AL is reported in the CMS Open Payments database as having received $53,619 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $344 2
2023 General $20 1
2022 General $19,210 59
2021 General $34,045 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James McMurtrie
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to James McMurtrie were reported at $0. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year James McMurtrie Sports Medicine median Middle half National median
2019 $0 $1,176 $199–$4,249 $163
2020 $0 $708 $96–$2,890 $114
2021 $34,045 $1,213 $152–$3,994 $132
2022 $19,210 $1,230 $159–$3,998 $149
2023 $20 $584 $146–$2,836 $160
2024 $344 $628 $163–$3,168 $164
2025 $0 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Arthrex, Inc. $24,718 23 payments
  2. Smith+Nephew, Inc. $22,430 16 payments
  3. Medical Device Business Services, Inc. $2,444 1 payment
  4. Stryker Corporation $2,000 14 payments
  5. Alon Medical Technology $1,200 1 payment
  6. DePuy Synthes Sales Inc. $340 7 payments
  7. Prime Surgical, LLC $264 7 payments
  8. Linvatec Corporation $175 1 payment
  9. Zimmer Biomet Holdings, Inc. $28 1 payment
  10. Pacira Pharmaceuticals Incorporated $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Education $25,000 8 payments
  2. Grant $22,444 2 payments
  3. Travel and Lodging $3,498 13 payments
  4. Food and Beverage $2,677 49 payments
Products named General payments · program years 2021–2024
  1. FAST-FIX $1,751 5 payments
  2. SALVATION $1,389 7 payments
  3. FIRSTPASS $1,197 4 payments
  4. ACUFEX Meniscal Root Repair $1,197 4 payments
  5. Bone Anchors with Arthroscopic Delivery System $209 2 payments
  6. BIOBRACE 23MM $175 1 payment
  7. AIR $158 1 payment
  8. COBRA $158 1 payment
  9. NANOTACK FLEX $156 1 payment
  10. ICONIX $136 1 payment
  11. Other $760 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

230

Median for Sports Medicine: 144

Drug cost

$831

Median for Sports Medicine: $1,027

Branded share of claims

0%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 29 $282
Meloxicam Generic 89 $230
Oxycodone Hcl Generic 43 $163
Tramadol Hcl Generic 34 $73
Ondansetron Hcl Generic 24 $48
Gabapentin Generic 11 $36

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$96,908

Of which drugs: $14,641

Medicare patients

304

Average age 73

Services billed

2,473

189 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 34%
Depression 31%
Diabetes 30%
Chronic kidney disease 22%
Atrial fibrillation 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 23 30 $11,968
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 133 937 $637

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record